liomys
Claire Bennett

Claire Bennett

Skin-care decisions

Routine Decisions · Ingredient Context

About

Covers the everyday calculus of a routine: when adding a step earns its place, when pausing one is the wiser move, and when simplifying beats stacking more products. The standard is plain: no recommendation ships without weighing the tradeoff it creates elsewhere in the routine.

Judgment here comes from reading routines as systems, not lists of products. Before writing, checks how a new step interacts with what is already in use, what concentration and formulation actually mean for that interaction, and what the documentation does not say. Will not publish a swap or an addition presented as universal when it only holds for a narrow set of conditions.

Desks

Contact

editorial@liomys.com

Published work 13 articles since 2026

  1. A Six-Day Course of Two Old Drugs Is Being Tested to Prevent Skin Cancer in Transplant Patients

    A six-day combo of two old generic drugs, vitamin D analog calcipotriene and chemo agent 5-fluorouracil, cut skin cancer recurrence fourfold in a 3-year study, and is now being tested in transplant patients.

  2. A Push for Pediatric Biologics Skips Over Why Clinicians Hesitate

    A conference Q&A urging dermatology clinicians to embrace immunologic pathways and push harder for pediatric biologics glosses over how narrow FDA-approved options for children actually are, and how much the message doubles as promotion for the sponsoring conference.

  3. A Newly Public Biotech Bets Against the Filler

    Conexeu Sciences is betting that rebuilding skin's collagen scaffold, not just adding volume, is the next frontier in aesthetics — and that GLP-1 drugs just created the patient population to prove it.

  4. A Dermatology Journal's Essay on a Chinese Ink Painting Isn't a Study

    The Journal of Investigative Dermatology's August 2026 issue carries a two-page Letters to the Editor essay, not a study, in which two dermatologists and an artist read Xu Beihong's 1930s ink painting Eight Horses as an argument for training clinicians to look closely; it cites no data for that claim.

  5. The Acne Bacterium Is Missing From This Anti-Acne Cream Study

    A new preclinical study of a Psorospermum febrifugum bark-extract cream reports lipase inhibition, sebum reduction, and dermal safety in rats, but never tests the finished cream against Cutibacterium acnes, the bacterium the condition is named for.

  6. A Hair-Growth Brake Gene, and What Happens When It's Actually Gone

    A new ex vivo study finds that FLCN, the gene mutated in Birt-Hogg-Dube syndrome, suppresses hair follicle growth in organ-cultured human follicles, but the syndrome it causes in real skin builds disorganized follicular growths, not fuller hair.

  7. A Skin-Color Angle Is Not a Fitzpatrick Type

    ITA calculates a color angle from lightness and yellowness. Converting its six categories into Fitzpatrick types adds a claim about sun reactivity that a photograph does not contain, even before lighting error is considered.

  8. When an Itch Has No Rash Behind It

    Itching with no visible rash has a documented but narrow link to cancer, strongest in Hodgkin lymphoma, where it can appear years before diagnosis yet doesn't track with tumor size. The biology behind it is still unresolved, and most unexplained itch traces back to something else entirely.

  9. Three Verdicts on the Same New Psoriasis Pill

    No trial has ever tested the new oral psoriasis drug icotrokinra against injectable IL-23 inhibitors head to head, and the indirect comparisons published so far, including two tied to the drugmakers involved, disagree with each other.

  10. What a New Skin-Cancer AI Paper's Author List Reveals

    A short communication published August 10 in the Journal of Investigative Dermatology reports a generative method for narrowing Fitzpatrick skin-tone disparities in AI skin-tumor classification; PubMed's affiliation records show the nine-person team spans hospitals in Seoul, the Philippines, and Ethiopia, a detail the paper's public summary leaves out.

  11. For Most Children With Alopecia Areata, No Systemic Drug Is Approved Yet

    A new retrospective study on predictors of systemic treatment response in pediatric alopecia areata went online this month with no public abstract yet, but the treatment landscape it examines is checkable now: only one systemic drug is FDA-approved for children with the condition, and only for ages twelve and up.

  12. The Sensitive-Skin Paper Calls a Galderma Trademark a Cornerstone

    A July 2026 expert advisory calls CTMP a cornerstone of sensitive-skin care; CTMP is a Galderma trademark, and Galderma funded the meeting and manuscript. Its disclosures also list two company employees as authors and personal fees from Galderma for the other authors.

  13. The Stool Test Doctors Are Debating Before a New Biologic

    A formal exchange in a major dermatology journal shows specialists still disagree about routinely testing for gut inflammation before starting bimekizumab for hidradenitis suppurativa, and the reply's byline mixes independent academics with employees of the drug's manufacturer.